venBio LLC is a private equity and venture capital firm specializing in investments in early venture, mid venture, late venture, turnaround, Consolidation, Spin-outs, PIPEs, mezzanine financing, and bridge financing. It seeks to invest in life sciences and healthcare sector. It targets investments in clinical stage private and public small cap companies with a therapeutic product, as well as medical technologies that enable better care for patients. venBio LLC was founded in June 2009 and is based in San Francisco, California with an additional office in New York, New York.

VenBio

Principal

Managing Partner

Outlook Therapeutics raised $31000000 on 2015-07-27 in Venture Round

Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics. It is advancing its pipeline of 11 biosimilar products, two of which are currently in clinical development. The company employs its BioSymphony biosimilars business model to achieve accelerated development and technical excellence in order to create affordable medicines for patients around the world.

Oncobiologics

CinCor Pharma raised $143000000 on 2021-10-12 in Series B

CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, develops clinical candidates for cardiovascular, metabolic, and kidney diseases. It focuses on developing CIN-107, a aldosterone synthase inhibitor for the treatment of resistant hypertension and primary aldosteronism. The company was founded in 2018 and is based in Cincinnati, Ohio.

CinCor Pharma

Pharvaris raised $66000000 on 2019-09-10 in Series B

Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated indications. PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study.

The co-founders of Pharvaris include an inventor of icatibant and the leadership from Jerini AG that developed icatibant for the treatment of HAE, now sold by Takeda under the brand name Firazyr®.

Pharvaris B.V.

Apellis Pharmaceuticals raised $60000000 on 2017-08-10 in Series E

Apellis Pharmaceuticals, Inc. is an early stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (COPD). Apellis emerged from a successful transaction between Potentia Pharmaceuticals, Inc. and Alcon Research, Ltd in October 2009 in which Alcon licensed the ocular applications of Potentia’s family of complement inhibitors.  Apellis holds the worldwide exclusive rights to the extra-ocular uses of these compounds. In May 2010, with start-up capital raised from private investors, Apellis commenced full-scale operations.

Apellis Pharmaceuticals, Inc.

Harmony Biosciences raised $270000000 on 2017-10-06 in Venture Round

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc. was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. The company was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.

Harmony Biosciences Holdings, Inc.

Artiva Biotherapeutics raised $120000000 on 2021-02-26 in Series B

Artiva Biotherapeutics, Inc., a biotech company, develops and manufactures cellular immunotherapies for cancer patients. The company offers a pipeline of off-the-shelf, allogeneic natural killer (NK) cell therapies for the treatment of hematologic cancers or solid tumors. The company’s products target CD20 and CD19 in B-cell lymphomas and HER2 in various solid tumors. The company was founded in 2019 and is headquartered in San Diego, California. Artiva Biotherapeutics, Inc. operates as a subsidiary of Green Cross Holdings Corporation.

Artiva Biotherapeutics, Inc.

HistoWiz raised $32250000 on 2021-10-19 in Series A

HistoWiz is a biotech company that automates the processing and digitizing of tissue samples for pharma and academia.

Through its fully automated histology lab and the world’s first online pathologist network, HistoWiz processes and annotates tissue samples which are stored on PathologyMap, its cloud database, as a resource for cancer researchers.

The data stored on PathologyMap enables the integration of technology and the development of AI tools for digital pathology on an unprecedented scale.

HistoWiz

Apellis Pharmaceuticals raised $47000000 on 2016-02-12 in Series D

Precision BioSciences raised $110000000 on 2018-06-08 in Series B

Precision BioSciences is a biotechnology company dedicated to improving lives through its next-generation gene editing technology, ARCUS.

Precision BioSciences’ mission is to translate the world’s most powerful genome editing technology into greatly needed products throughout the life sciences. Precision’s proprietary ARCUS genome editing technology enables the production of highly specific nucleases that can insert, remove, and modify DNA at essentially any location in a complex genome.

Precision BioSciences, Inc.

Checkmate Pharmaceuticals raised $85000000 on 2020-06-10 in Series C

Checkmate Pharmaceuticals, Inc., a biotechnology company, develops novel immunotherapies for the treatment of cancer. It engages in the field of CpG oligonucleotides and validates an approach that combines the ability of CpG DNA to activate an anti-tumor T-cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Checkmate Pharmaceuticals, Inc.

ImmPACT Bio raised $111000000 on 2022-01-20 in Series B

ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.

ImmPACT Bio USA

Impel NeuroPharma raised $67500000 on 2018-12-06 in Series D

Impel NeuroPharma is a medical device company developing a novel drug delivery device that enables drugs to bypass the blood-brain barrier(BBB) using direct nose-to-brain delivery. It is focused on developing transformative therapies that unlock the full potential of therapeutic molecules for people living with CNS disorders with high unmet medical needs. 

The company was founded in 2008 and is headquartered in Seattle, Washington.

Impel NeuroPharma

Solstice Biologics raised $7500000 on 2012-12-28 in Private Equity Round

Solstice Biologics is a biotech company that provides solutions for targeting and delivering nucleic acid therapeutics. The Company specializes in the development of small, cell-permeable RNAi pro-drugs that can enter many different cell types and deliver on the promise of RNAi therapeutics.

It was established in 2012 and is based in San Francisco, California.

Solstice Biologics

Tallac Therapeutics raised $62000000 on 2020-12-01 in Series A

Tallac Therapeutics, Inc. develops immunotherapies for cancer patients. Tallac Therapeutics, Inc. was formerly known as Tollnine, Inc. The company was founded in 2018 and is based in Burlingame, California.

Tallac Therapeutics

ACELYRIN raised $250000000 on 2021-11-16 in Series B

ACELYRIN

RayzeBio raised $108000000 on 2021-06-15 in Series C

RayzeBio, Inc. is a biotechnology company that develops tumor-targeted small molecule medicines that harness the power of radioisotopes. The company provides macrocyclic peptide mimetic binders to deliver therapeutic radioisotopes, such as Actinium-225, an alpha-emitter for solid tumors. RayzeBio, Inc. was founded in 2020 and is based in San Diego, California.

RayzeBio

ALX Oncology raised $25000000 on 2017-03-31 in Convertible Note

ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer. It is an independent, private biotechnology company.

The founding of Alexo Therapeutics was based upon technology invented by Aaron Ring, K. Christopher Garcia, Kipp Weiskopf, Aron Levin, and Irving Weissman at Stanford University. This discovery involves soluble versions of signal regulatory protein-α (SIRPα) that have been engineered to bind CD47 with significantly greater affinity than natural SIRPα.1.

Alexo Therapeutics Limited

Ablaze Pharmaceuticals raised $75000000 on 2021-11-29 in Series A

Ablaze Pharmaceuticals

Stem Cell Therapeutics raised $33000000 on 2013-12-16 in Venture Round

Stem Cell Therapeutics Corp. (TSX-V: SSS), a Toronto-based biopharmaceutical development company, is Canada’s only public company dedicated to advancing cancer stem cell discoveries into novel and innovative cancer therapies. Building on over half a century of leading groundbreaking Canadian stem cell research, we are supported by established links to multiple Toronto academic institutes and oncology treatment centres that represent one of the world’s most acclaimed cancer research hubs.

Stem Cell Therapeutics

RayzeBio raised $45000000 on 2020-10-14 in Series A

Ceptur Therapeutics raised $75000000 on 2022-01-19 in Series A

Silagene is a biotech company developing technology designed to facilitate the creation of U1 adaptors with therapeutic potential. The company's technology overcomes the limitations of gene silencing technologies, enabling doctors to to treat patients with various types of cancers.

It was founded in 2008 and is based in Hillsborough, New Jersey, United States.

Silagene

NorthSea Therapeutics raised $80000000 on 2021-12-17 in Series C

NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generated pipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models.

NorthSea Therapeutics

ALX Oncology raised $105000000 on 2020-02-12 in Series C

Fog Pharmaceuticals raised $23271035 on 2021-01-04 in Venture Round

FogPharma derives financial support from a unique syndicate of extraordinary private and institutional investors. FogPharma’s network of friends includes our founders, employees, investors, advisors, collaborators, and cancer patients; all working together to pioneer a unique approach toward conquering cancer.

FogPharma is laser-focused and unstoppable in its mission to deliver the new class of medicines to patients and their families to bring them years to life and life to years.

Fog Pharmaceuticals, Inc.

Bellicum Pharmaceuticals raised $55000000 on 2014-08-27 in Series C

Bellicum Pharmaceuticals is a clinical stage company developing next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases. Bellicum's novel approach is to utilize precise knowledge of the signaling pathways that regulate the immune response to target specific factors that can influence the potency and duration of this response.

Bellicum Pharmaceuticals, Inc.

Neurogastrx raised $60000000 on 2021-08-26 in Series B

Neurogastrx, Inc. manufactures biopharmaceutical products for the treatment of gastrointestinal disorders. The company develops product such as NG101 that increases gastric motility and contains antiemetic properties. Neurogastrx, Inc. was incorporated in 2017 and is based in Campbell, California.

Neurogastrx, Inc.

NorthSea Therapeutics raised $40006978 on 2020-01-08 in Series B

Ventyx Biosciences raised $51000000 on 2021-09-20 in Series B

Ventyx Biosciences is a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high-value targets.

Ventyx Biosciences, Inc.

RayzeBio raised $105000000 on 2020-12-08 in Series B

NFlection Therapeutics raised $20000000 on 2020-06-09 in Series A

NFlection Therapeutics, Inc., a biotechnology company, focuses on the discovery and development of targeted therapies for rare disorders. It offers therapies, such as RASopathies that are driven by the aberrant activation of the Ras/Raf/MEK/ERK pathway. The company also develops soft mitogen-activated protein kinase (MEK) to mitigate and treat cutaneous neurofibromas in neurofibromatosis type 1. NFlection Therapeutics, Inc. was incorporated in 2014 and is based in Wayne, Pennsylvania.

NFlection Therapeutics

Stargazer Pharmaceuticals raised $57000000 on 2020-11-09 in Series A

Stargazer Pharmaceuticals Inc., a biopharmaceutical company, develops and manufactures therapies for eye diseases. It offers a treatment for Stargardt’s disease, a form of juvenile retinal degeneration. Stargazer Pharmaceuticals Inc. was founded in 2018 and is based in Boston, Massachusetts.

Stargazer Pharmaceuticals Inc.

ACELYRIN raised $300000000 on 2022-09-13 in Series C

Cytos raised $40000000 on 2012-03-21 in Post-IPO Equity

Cytos is a public biopharmaceutical company focused on the development of targeted immunotherapies with a VLP B-cell vaccines platform and ongoing preclinical development programs based on the platform.

Cytos

Attralus raised $116000000 on 2021-09-08 in Series B

Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Its proprietary peptide-based pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis. The company is focused on targeting common pathology in all systemic amyloidosis diseases, with the goal of developing treatments for all subtypes of amyloidosis, including the majority in which there are currently no treatment options.

Attralus

INBRACE raised $102000000 on 2021-09-08 in Series D

Swift Health Systems Inc., a medical device company, develops invisible orthodontic solutions. The company develops InBrace, an orthodontic system that is hidden behind the teeth to correct malocclusion (crooked teeth). Swift Health Systems Inc. was incorporated in 2014 and is based in Irvine, California.

Swift Health Systems Inc.

Ventyx Biosciences raised $114000000 on 2021-03-09 in Venture Round

Elevation Oncology raised $65000000 on 2020-11-18 in Series B

Elevation Oncology, Inc., a biotechnology company, focuses on the development of precision medicines for patients with genomically defined cancers. It offers drugs that inhibit the specific alterations identified as drivers of cancer; and treats solid tumors with the NRG1 genomic fusion. Elevation Oncology, Inc. was formerly known as 14ner Oncology, Inc. The company was incorporated in 2019 and is based in New York, New York.

Elevation Oncology

Solstice Biologics raised $18000000 on 2013-01-04 in Series A

Precision BioSciences raised $25650000 on 2015-05-11 in Series A

Aurinia Pharmaceuticals raised $52000000 on 2014-02-14 in Post-IPO Equity

Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the potential treatment of lupus nephritis, focal segmental glomerulosclerosis, and Dry Eye Syndrome. The company is headquartered in Victoria, British Columbia and focuses its development efforts globally.

Aurinia Pharmaceuticals Inc.

Outlook Therapeutics raised an undisclosed amount on 2015-09-29 in Venture Round

Menlo Therapeutics raised $50500000 on 2017-07-18 in Series C

As of March 9, 2020, Menlo Therapeutics Inc. was acquired by Foamix Pharmaceuticals Ltd., in a reverse merger transaction. Menlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis; psoriasis; chronic pruritus; atopic dermatitis; and refractory chronic cough. The company was formerly known as Tigercat Pharma, Inc. and changed its name to Menlo Therapeutics Inc. in May 2016. Menlo Therapeutics Inc. was founded in 2011 and is headquartered in Redwood City, California.

Menlo Therapeutics

Adaptimmune raised $104000000 on 2014-09-25 in Series A

Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroys cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses.

The company was incorporated in 2007 and is based in Abingdon, United Kingdom.

Adaptimmune

Checkmate Pharmaceuticals raised $27000000 on 2017-06-15 in Series B

Aeovian Pharmaceuticals raised $37000000 on 2019-10-03 in Series A

Aeovian Pharmaceuticals, Inc. develops and commercializes therapeutics for the treatment of age-related and other diseases. The company's therapeutics inhibit the mTORC1 and mTORC2 pathways that address the underlying causes of disease initiation and progression, such as oxidative, cellular, and environmental stress. Aeovian Pharmaceuticals, Inc. was formerly known as Delos Pharmaceuticals, Inc. The company was founded in 2012 and is based in San Francisco, California.

Aeovian Pharmaceuticals, Inc.

Metacrine raised $36000000 on 2015-08-05 in Series A

Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.

Metacrine

Akero Therapeutics raised $65000000 on 2018-06-25 in Series A

Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.

Akero Therapeutics

Pharvaris raised $80000000 on 2020-11-18 in Series C

Cidara Therapeutics raised $42000000 on 2015-02-11 in Series B

Cidara Therapeutics is a biotechnology company that specializes in the fields of healthcare and therapeutics. The company focuses on developing innovative therapies to treat life-threatening illnesses exacerbated by deficiencies of the human immune system. 

Cidara Therapeutics was founded in 2012 and headquartered in San Diego, California.

Cidara Therapeutics

ALX Oncology raised $36000000 on 2015-03-18 in Series A

Seragon Pharmaceuticals raised $30000000 on 2013-10-16 in Series A

Seragon Pharmaceuticals, Inc., headquartered in Irvine, California, is a research-based biopharmaceutical company dedicated to improving human and animal health through innovative science. Seragon Pharmaceuticals is committed to applying cutting-edge scientific and technological advancements to the fields of metabolism, gene therapy and bioinformatics. From the research end to consumer products and clinical applications, Seragon strives to bring people access to the most significant breakthroughs in medicine. For more information, please visit www.seragon.com

Seragon Pharmaceuticals

Impel NeuroPharma raised $36000000 on 2016-12-02 in Series C

Turning Point Therapeutics raised $80000000 on 2018-10-19 in Venture Round

Turning Point Therapeutics, Inc. is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases.  We are focusing on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity.

TP Therapeutics

Checkmate Pharmaceuticals raised $20000000 on 2015-08-12 in Series A

Labrys Biologics raised $31000000 on 2013-01-03 in Series A

Labrys Biologics Inc., a company focused on treatments for chronic migraine. 

Labrys Biologics has acquired worldwide rights to RN-307 from Pfizer Inc. RN-307 is an antibody for the treatment of chronic migraine.

Labrys Biologics

Metacrine raised $22000000 on 2017-12-07 in Series B

Neurogastrx raised $45000000 on 2018-01-04 in Series A

Artiva Biotherapeutics raised $78000000 on 2020-06-26 in Series A

Aragon Pharmaceuticals raised $50000000 on 2012-10-04 in Series D

Aragon Pharmaceuticals is a discovery-stage small molecule company focused on therapeutics for the treatment of hormone-resistant cancers, with an initial focus on prostate and breast cancer.

Aragon Pharmaceuticals

Swift Health Systems raised $45000000 on 2019-10-08 in Series C

Attralus raised $25000000 on 2020-09-14 in Series A

Metacrine raised $65000000 on 2018-06-06 in Series C

Akero Therapeutics raised $70000000 on 2018-12-12 in Series B

Arrakis Therapeutics raised $75000000 on 2019-04-18 in Series B

Arrakis Therapeutics is a developer of a drug discovery platform intended to target RNA. The company's platform integrates leading-edge RNA bioinformatic and structural tools to produce a pipeline of rSMs to treat a range of disease including neurology, oncology and rare genetic diseases, enabling physicians to offer enhanced care.

Arrakis Therapeutics

Heart Metabolics raised $20000000 on 2014-04-16 in Series A

Heart Metabolics Limited is pioneering a pharmaceutical therapy for the treatment of hypertrophic cardiomyopathy (“HCM”).

HCM is a condition in which the heart muscle becomes thick. The thickening makes it harder for blood to leave the heart forcing the heart to work harder to pump blood, leading in many cases to heart failure. Sudden death is caused frequently.

There are over 100,000 cases of HCM in the United States alone, often presenting more severely in young adults and athletes; unfortunately the younger the individual is when diagnosed with HCM, the more likely that the individual has a severe form.

Although various cardiovascular drugs are currently used to treat HCM, there are patients who are not being helped by current therapeutics. In response to this medical need and based on encouraging phase II clinical trial results to date, Heart Metabolics is developing perhexiline as a therapeutic for all types of HCM. Perhexiline is currently an approved drug in Australia and New Zealand for the treatment of angina.

Heart Metabolics plans to conduct clinical trials in the U.S. and seek FDA approval of perhexiline as an orphan drug; the company currently has such an orphan designation from the FDA.

Heart Metabolics

Checkmate Pharmaceuticals raised $22000000 on 2018-12-12 in Series C